| Literature DB >> 19592567 |
Ambroise Garry1, David H Edwards, Ian F Fallis, Robert L Jenkins, Tudor M Griffith.
Abstract
AIMS: Our objective was to investigate whether pro-oxidant properties of ascorbic acid (AA) and tetrahydrobiopterin (BH(4)) modulate endothelium-dependent, electrotonically mediated arterial relaxation. METHODS ANDEntities:
Mesh:
Substances:
Year: 2009 PMID: 19592567 PMCID: PMC2761203 DOI: 10.1093/cvr/cvp235
Source DB: PubMed Journal: Cardiovasc Res ISSN: 0008-6363 Impact factor: 10.787
Effects of pharmacological interventions on EDHF-type relaxations evoked by CPA and ACh by in the presence and absence of H2O2 or catalase
| CPA | pIC50 | ACh | pEC50 | ||||
|---|---|---|---|---|---|---|---|
| Control | 5 | 4.61 ± 0.01 | 92.8 ± 2.1 | Control | 5 | 6.55 ± 0.09 | 75.8 ± 2.7 |
| Catalase | 5 | 4.66 ± 0.07 | 93.8 ± 2.4 | Catalase | 5 | 6.64 ± 0.08 | 77.2 ± 3.3 |
| AA | 5 | 5.12 ± 0.05*** | 92.3 ± 2.3 | AA | 5 | 7.00 ± 0.06* | 81.9 ± 1.2 |
| AA+catalase | 5 | 4.59 ± 0.11 | 91.5 ± 3.0 | AA+catalase | 5 | 6.48 ± 0.10 | 75.3 ± 2.2 |
| Control | 7 | 4.70 ± 0.10 | 79.6 ± 5.4 | Control | 6 | 6.43 ± 0.08 | 76.6 ± 3.8 |
| Catalase | 7 | 4.74 ± 0.04 | 85.8 ± 2.5 | Catalase | 6 | 6.39 ± 0.10 | 73.1 ± 3.6 |
| BH4 | 7 | 5.39 ± 0.15*** | 85.1 ± 2.1 | BH4 | 6 | 6.91 ± 0.04** | 79.7 ± 3.1 |
| BH4+catalase | 7 | 4.76 ± 0.05 | 83.9 ± 2.5 | BH4+catalase | 6 | 6.42 ± 0.08 | 71.2 ± 3.9 |
| Control | 7 | 4.64 ± 0.04 | 84.3 ± 3.1 | Control | 8 | 6.50 ± 0.06 | 74.9 ± 4.4 |
| H2O2 (10 µM) | 7 | 4.80 ± 0.04 | 90.3 ± 1.6 | H2O2 (10 µM) | 7 | 6.55 ± 0.08 | 72.7 ± 5.2 |
| H2O2 (30 µM) | 7 | 4.96 ± 0.10 | 91.6 ± 2.5 | H2O2 (30 µM) | 6 | 6.87 ± 0.20 | 76.8 ± 5.5 |
| H2O2 (100 µM) | 7 | 5.36 ± 0.17*** | 86.0 ± 2.5 | H2O2 (100 µM) | 9 | 7.25 ± 0.15*** | 74.7 ± 4.1 |
| Control | 4 | 4.80 ± 0.03 | 92.6 ± 1.4 | Control | 7 | 6.46 ± 0.09 | 69.0 ± 3.0 |
| SOD (1200 U) | 4 | 4.71 ± 0.04 | 84.1 ± 2.0 | SRPETK | 7 | — | 26.5 ± 7.3*** |
| AA | 4 | 5.53 ± 0.19** | 87.5 ± 3.6 | srptek | 5 | 6.29 ± 0.24 | 68.9 ± 5.6 |
| AA+SOD | 4 | 5.53 ± 0.15** | 90.2 ± 2.0 | ||||
| Control | 4 | 4.67 ± 0.16 | 93.4 ± 3.2 | Control | 7 | 6.63 ± 0.10 | 77.9 ± 5.4 |
| SOD (1200 U) | 4 | 4.66 ± 0.06 | 80.0 ± 7.9 | SRPTEK | 7 | — | 34.2 ± 8.9** |
| BH4 | 4 | 6.01 ± 0.20*** | 88.1 ± 7.1 | SRPTEK+H2O2 | 5 | — | 39.0 ± 11.1* |
| BH4+SOD | 4 | 5.39 ± 0.21* | 85.5 ± 9.1 | H2O2 (100 µM) | 5 | 7.16 ± 0.1** | 74.6 ± 7.1 |
| Control | 6 | 4.92 ± 0.11 | 78.0 ± 7.6 | ||||
| 43Gap26 (100 µM) | 6 | - | 30.6 ± 6.9** | ||||
| 43Gap26+H2O2 | 4 | 5.03 ± 0.17 | 73.5 ± 10.4 | ||||
| H2O2 (100 µM) | 4 | 6.31 ± 0.15*** | 72.8 ± 7.9 | ||||
| Control | 6 | 4.73 ± 0.05 | 83.1 ± 3.8 | ||||
| YDKSFPISHVR (300 µM) | 4 | - | 35.2 ± 14.1*** | ||||
| YDKSFPISHVR+H2O2 | 4 | 4.59 ± 0.01 | 80.2 ± 3.3 | ||||
| H2O2 (100 µM) | 6 | 5.30 ± 0.11*** | 84.3 ± 4.2 |
Potency (negative log IC50 or EC50) and maximal relaxation (Rmax) expressed as a percentage of the constrictor response to phenylephrine are given as mean ± SEM.
*P < 0.05 compared with control.
**P < 0.01 compared with control.
***P < 0.001 compared with control.
Effects of adventitially applied H2O2 on EDHF-type dilatations evoked by CPA and ACh
| pEC50 | |||
|---|---|---|---|
| CPA | |||
| Control | 5 | 4.79 ± 0.04 | 88.0 ± 2.3 |
| H2O2 (100 µM) | 5 | 5.09 ± 0.05* | 91.4 ± 2.9 |
| Ach | |||
| Control | 5 | 6.30 ± 0.08 | 78.2 ± 4.7 |
| H2O2 (100 µM) | 5 | 6.75 ± 0.09* | 82.6 ± 2.0 |
Potency (negative log EC50) and maximal dilatation (Dmax) expressed as a percentage of the dilator response to SNP are given as mean ± SEM.
*P < 0.01 compared with control.